稳定化透明质酸(sHA)凝胶作为乳腺癌瘤床腔新型标记物的手术可行性
本研究在35例接受保乳手术的乳腺癌患者中,由外科医生将稳定化透明质酸(sHA)凝胶以约1厘米小滴注入切除腔周围壁,评估手术可行性。所有患者均成功完成sHA凝胶插入,中位增加手术室时间2.8分钟,89%的患者被外科医生评为「容易」。5例(14%)患者发生2级或以上不良事件,其中2例为3级不良事件(血肿和感染性血清肿),所有患者均恢复并接受计划的辅助治疗。作者结论认为sHA凝胶作为标记物有助于定义保乳术后辅助MRI-based放疗计划的瘤床腔,手术可行。
要点
- 35例保乳手术患者均成功完成sHA凝胶插入,中位增加手术室时间2.8分钟。
- 外科医生对89%的患者评价插入「容易」。
- 5例(14%)发生2级或以上不良事件,其中3例口服抗生素治疗乳腺感染,2例为3级不良事件(血肿和感染性血清肿)。
核心结论
- sHA凝胶作为标记物帮助定义保乳术后辅助MRI-based放疗计划的瘤床腔,手术可行。
研究设计与样本
- 研究在手术室由乳腺外科医生将稳定化透明质酸(sHA)凝胶以约1厘米小滴注入切除腔周围壁,评估手术可行性。
主要发现
- 35例患者全部成功完成sHA凝胶插入,中位增加手术室时间2.8分钟,89%的患者被外科医生评为「容易」。
- 手术室内无即刻不良事件,5例(14%)患者发生2级或以上不良事件。
- 5例中3例因乳腺感染口服抗生素,2例发生3级不良事件:1例血肿需保乳术后第1天在手术室清除,1例感染性血清肿需保乳术后2个月在手术室引流冲洗。
- 5例患者均恢复并接受计划的乳腺癌辅助治疗,不良事件数据反映标准保乳手术的常见风险,不能明确单独归因于sHA凝胶插入。
关键数值与推荐
- 手术可行性由sHA凝胶插入成功率、外科医生评价的插入容易度、插入所需时间、使用量及与sHA凝胶插入相关的不良事件确定。
- 2级或以上不良事件发生率为14%(5/35),其中3级不良事件2例。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 不良事件数据反映标准保乳手术的常见风险,不能明确单独归因于sHA凝胶插入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Consistent delineation of the breast conserving surgery (BCS) tumour bed (TB) for breast cancer remains a challenge for radiation oncologists. Accurate delineation allows for better local control and reduces toxicity when planning partial breast or TB boost radiation therapy (RT). METHODS: In the operating theatre (OT) breast surgeons inserted stabilised hyaluronic acid (sHA) gel as small drops approximately one cm into the walls surrounding the resection cavity. Surgical feasibility was determined by the rate of successful sHA gel insertion procedure, the ease of insertion as rated by surgeons, the time required for insertion procedure, the quantity used, and any adverse events (AE) relating to sHA gel insertion. RESULTS: Thirty-five patients were enrolled. All patients underwent sHA gel insertion successfully. The procedure added a median of 2.8 min to the OT time and was rated as 'easy' in 89 % of patients. There were no immediate AE in OT. Five (14 %) patients experienced a grade 2 or higher AE. Three of the five patients were prescribed oral antibiotics for breast infection. Two of the five patients experienced a grade 3 AE - haematoma which required evacuation in OT day 1 post-BCS, and infected seroma which required drainage and washout in OT 2 months post-BCS. All five patients recovered and underwent the planned adjuvant therapies for their BC. The AE data reflects common risks with standard BCS and are not clearly attributed to sHA gel insertion alone. CONCLUSION: We show that sHA gel is surgically feasible as a marker to help define the TB cavity for post-BCS adjuvant MRI-based RT planning.
引用
- Yeh J, Chew G, Ng SL, et al. Stabilised Hyaluronic Acid (sHA) gel as a novel marker for breast cancer tumour bed cavity: Surgical feasibility. Clin Transl Radiat Oncol. 2024. PMID: 38406647. doi:10.1016/j.ctro.2024.100745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。